Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Ramucirumab DP|BIOLOGICAL: IMC-18F1|DRUG: Capecitabine
Sponsor: Eli Lilly and Company